| Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells N Gagliani, CF Magnani, S Huber, ME Gianolini, M Pala, P Licona-Limon, ... Nature medicine 19 (6), 739-746, 2013 | 885 | 2013 |
| Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10–dependent ILT4/HLA-G pathway S Gregori, D Tomasoni, V Pacciani, M Scirpoli, M Battaglia, CF Magnani, ... Blood, The Journal of the American Society of Hematology 116 (6), 935-944, 2010 | 616 | 2010 |
| Targeting of acute myeloid leukaemia by cytokine‐induced killer cells redirected with a novel CD 123‐specific chimeric antigen receptor S Tettamanti, V Marin, I Pizzitola, CF Magnani, GMP Giordano Attianese, ... British journal of haematology 161 (3), 389-401, 2013 | 266 | 2013 |
| Killing of myeloid APCs via HLA class I, CD2 and CD226 defines a novel mechanism of suppression by human Tr1 cells CF Magnani, G Alberigo, R Bacchetta, G Serafini, M Andreani, ... European journal of immunology 41 (6), 1652-1662, 2011 | 180 | 2011 |
| Balance of anti-CD123 chimeric antigen receptor binding affinity and density for the targeting of acute myeloid leukemia S Arcangeli, MC Rotiroti, M Bardelli, L Simonelli, CF Magnani, A Biondi, ... Molecular therapy 25 (8), 1933-1945, 2017 | 160 | 2017 |
| Sleeping Beauty–engineered CAR T cells achieve antileukemic activity without severe toxicities CF Magnani, G Gaipa, F Lussana, D Belotti, G Gritti, S Napolitano, ... The Journal of clinical investigation 130 (11), 6021-6033, 2020 | 122 | 2020 |
| Enforced IL-10 expression confers type 1 regulatory T cell (Tr1) phenotype and function to human CD4+ T cells G Andolfi, G Fousteri, M Rossetti, CF Magnani, T Jofra, G Locafaro, ... Molecular Therapy 20 (9), 1778-1790, 2012 | 108 | 2012 |
| Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells R Myburgh, JD Kiefer, NF Russkamp, CF Magnani, N Nuñez, A Simonis, ... Leukemia 34 (10), 2688-2703, 2020 | 60 | 2020 |
| Role of human leukocyte antigen-G in the induction of adaptive type 1 regulatory T cells S Gregori, CF Magnani, MG Roncarolo Human immunology 70 (12), 966-969, 2009 | 59 | 2009 |
| Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform CF Magnani, N Turazzi, F Benedicenti, A Calabria, E Tenderini, ... Oncotarget 7 (32), 51581, 2016 | 54 | 2016 |
| The past, present, and future of non-viral CAR T cells A Moretti, M Ponzo, CA Nicolette, IY Tcherepanova, A Biondi, CF Magnani Frontiers in immunology 13, 867013, 2022 | 52 | 2022 |
| Transposon-based CAR T cells in acute leukemias: where are we going? CF Magnani, S Tettamanti, G Alberti, I Pisani, A Biondi, M Serafini, ... Cells 9 (6), 1337, 2020 | 42 | 2020 |
| Preclinical efficacy and safety of CD19CAR cytokine-induced killer cells transfected with sleeping beauty transposon for the treatment of acute lymphoblastic leukemia CF Magnani, C Mezzanotte, C Cappuzzello, M Bardini, S Tettamanti, ... Human gene therapy 29 (5), 602-613, 2018 | 39 | 2018 |
| Targeting CD33 in chemoresistant AML patient-derived xenografts by CAR-CIK cells modified with an improved SB transposon system MC Rotiroti, C Buracchi, S Arcangeli, S Galimberti, MG Valsecchi, ... Molecular Therapy 28 (9), 1974-1986, 2020 | 38 | 2020 |
| Redirecting T cells with Chimeric Antigen Receptor (CAR) for the treatment of childhood acute lymphoblastic leukemia A Biondi, CF Magnani, S Tettamanti, G Gaipa, E Biagi Journal of autoimmunity 85, 141-152, 2017 | 23 | 2017 |
| Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors S Tettamanti, CF Magnani, A Biondi, E Biagi Immunology letters 155 (1-2), 43-46, 2013 | 23 | 2013 |
| Therapeutic and diagnostic applications of minor histocompatibility antigen HA-1 and HA-2 disparities in allogeneic hematopoietic stem cell transplantation: a survey of … S Di Terlizzi, E Zino, B Mazzi, C Magnani, C Tresoldi, SK Perna, M Bregni, ... Biology of Blood and Marrow Transplantation 12 (1), 95-101, 2006 | 23 | 2006 |
| Engineered T cells towards TNFRSF13C (BAFFR): a novel strategy to efficiently target B‐cell acute lymphoblastic leukaemia. N Turazzi, G Fazio, V Rossi, A Rolink, G Cazzaniga, A Biondi, ... British journal of haematology 182 (6), 2018 | 19 | 2018 |
| Donor-derived CD19-targeted T cells in allogeneic transplants CF Magnani, A Biondi, E Biagi Current Opinion in Hematology 22 (6), 497-502, 2015 | 19 | 2015 |
| Low-Dose Lenalidomide Improves CAR-Based Immunotherapy In CLL By Reverting T-Cell Defects In Vivo MTS Bertilaccio, S Tettamanti, GMPG Attianese, G Galletti, S Arcangeli, ... Blood 122 (21), 4171, 2013 | 16 | 2013 |
